Rezolute Gets FDA Clearance for RZ358 to Treat Hypoglycemia in Tumor Hyperinsulinism
Portfolio Pulse from Benzinga Newsdesk
Rezolute, Inc. (NASDAQ:RZLT) has received FDA clearance for its Investigational New Drug (IND) application for RZ358 to treat hypoglycemia in patients with tumor hyperinsulinism. The company plans to start patient enrollment in the first half of 2025.
August 05, 2024 | 11:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rezolute, Inc. received FDA clearance for its IND application for RZ358 to treat hypoglycemia in tumor hyperinsulinism. The company plans to start patient enrollment in the first half of 2025.
FDA clearance is a significant milestone for Rezolute, indicating regulatory approval to proceed with clinical trials. This news is likely to positively impact the stock price in the short term as it demonstrates progress in their drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100